News
BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update At BIO CEO & Investor Conference
BioSante Pharmaceuticals, Inc. will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual...
Press Releases
Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada(R) and TMC278
Gilead Sciences, Inc. announced that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet...
Press Releases
Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement for Elan’s Antibody-Based Therapeutics Pipeline
Elan plc and Boehringer Ingelheim announced that they have entered into a global technical development and manufacturing agreement for antibody-based therapeutics. Under the terms...
Drug Research
Shire Strengthens Specialty Pharmaceuticals Team with Senior R&D Appointments
Shire plc, the global specialty biopharmaceutical company, today announced the appointment of two senior Research & Development executives to its Specialty Pharmaceuticals business. Lawson...
News
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism
GlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme. Kenya is the first African country to receive pneumococcal...
Clinical Trials
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. announced publication of the BLISS-52 study of Benlysta® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus...
Press Releases
Cancer Can Be Prevented-Latest cancer preventability data released to mark World Cancer Day
On World Cancer Day, new independent evidence confirms that the increasing global trend of unhealthy and sedentary lifestyles is responsible for putting millions at...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read